[1] 陈小松, 沈坤炜. 乳腺癌多基因阵列表达谱检测与个体化治疗[J]. 中华外科杂志,2017,55(2):99-103.
[2] Perou CM, Sorlie T, Eisen MB, et al.Molecular portraits of human breast tumours[J]. Nature,2000,406(6797):747-752.
[3] Paik S, Shak S, Tang G, et al.A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med,2004,351(27):2817-2826.
[4] van de Vijver MJ, He YD, van 't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer[J]. N Engl J Med,2002,347(25):1999-2009.
[5] Dubsky P, Brase JC, Jakesz R, et al.The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients[J]. Br J Cancer,2013,109(12):2959-2964.
[6] Filipits M, Nielsen TO, Rudas M, et al.The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer[J]. Clin Cancer Res,2014,20(5):1298-1305.
[7] Paik S, Tang G, Shak S, et al.Gene expression and be-nefit of chemotherapy in women with node-negative, estro-gen receptor-positive breast cancer[J]. J Clin Oncol,2006, 24(23):3726-3734.
[8] Sparano JA, Gray RJ, Makower DF, et al.Prospective validation of a 21-gene expression assay in breast cancer[J]. N Engl J Med,2015,373(21):2005-2014.
[9] Sparano JA, Gray RJ, Makower DF, et al.Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med,2018,379(2):111-121.
[10] Sparano JA, Gray RJ, Ravdin PM, et al.Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J]. N Engl J Med,2019,380(25):2395-2405.
[11] Albain KS, Barlow WE, Shak S, et al.Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial[J]. Lancet Oncol,2010,11(1):55-65.
[12] Nitz U, Gluz O, Clemens M, et al.West German Study PlanB Trial: Adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of do-cetaxel and cyclophosphamide in HER2-negative early breast cancer[J]. J Clin Oncol,2019,37(10):799-808.
[13] Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med,2016,375(8):717-729.
[14] Krop I, Ismaila N, Andre F, et al.Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of Clinical Oncology Clinical Practice Guideline focused update[J]. J Clin Oncol,2017,35(24):2838-2847.
[15] Pan H, Gray R, Braybrooke J, et al.20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med,2017,377(19):1836-1846.
[16] Ma XJ, Wang Z, Ryan PD, et al.A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen[J]. Cancer Cell,2004,5(6):607-616.
[17] Sgroi DC, Sestak I, Cuzick J, et al.Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population[J]. Lancet Oncol,2013,14(11):1067-1076.
[18] Sestak I, Buus R, Cuzick J, et al.Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a rando-mized clinical trial[J]. JAMA Oncol,2018,4(4):545-553.
[19] Carey LA, Berry DA, Cirrincione CT, et al.Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase Ⅲ trial of paclitaxel plus trastuzumab with or without lapatinib[J]. J Clin Oncol,2016,34(6):542-549.
[20] Perez EA, Ballman KV, Mashadi-Hossein A, et al. Intrinsic subtype and therapeutic response among HER2-positive breaty st tumors from the NCCTG (Alliance) N9831 trial[J]. J Natl Cancer Inst,2016,28:109(2). pii: djw207.
[21] von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med,2017,377(2):122-131.
[22] Krop I, Paulson JN, Campbell C, et al.Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab(P) in HER2+ breast cancer(BC): Biomarker analysis of the APHINITY trial[J]. J Clin Oncol,2019, 37(15S):37S.
[23] Lehmann BD, Bauer JA, Chen X, et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest,2011,121(7):2750-2767.
[24] Jiang YZ, Ma D, Suo C, et al.Genomic and transcripto-mic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell,2019,35(3):428-440.
